Regulatory Relief Explored for QbD Use in Post-Approval Changes

There is little evidence that using QbD for managing post-approval changes will confer regulatory relief to pharmaceutical manufacturers. FDA and industry officials say that current FDA guidance documents on change control are not keeping up with the science.